Adage Capital Partners GP L.L.C. Lowers Position in AbbVie Inc. $ABBV

Adage Capital Partners GP L.L.C. decreased its stake in AbbVie Inc. (NYSE:ABBV) by 10.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,618,841 shares of the company’s stock after selling 179,892 shares during the quarter. AbbVie makes up 0.5% of Adage Capital Partners GP L.L.C.’s portfolio, making the stock its 27th biggest holding. Adage Capital Partners GP L.L.C. owned 0.09% of AbbVie worth $300,489,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in AbbVie by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock worth $32,910,186,000 after acquiring an additional 3,380,842 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of AbbVie by 2.4% in the second quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company’s stock worth $7,240,169,000 after purchasing an additional 924,761 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of AbbVie by 6.0% in the second quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock worth $4,970,848,000 after purchasing an additional 1,517,222 shares during the period. Norges Bank purchased a new stake in shares of AbbVie in the second quarter worth $4,288,200,000. Finally, Northern Trust Corp raised its position in shares of AbbVie by 0.9% during the 1st quarter. Northern Trust Corp now owns 22,013,920 shares of the company’s stock valued at $4,612,357,000 after purchasing an additional 189,294 shares during the period. Institutional investors own 70.23% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on ABBV shares. Bank of America upped their target price on shares of AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Morgan Stanley boosted their price objective on AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a research report on Friday. Evercore ISI upped their price objective on AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research note on Monday, September 22nd. DZ Bank downgraded AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price on the stock. in a research note on Tuesday, November 4th. Finally, BMO Capital Markets boosted their price target on AbbVie from $215.00 to $240.00 and gave the stock an “outperform” rating in a report on Friday, September 12th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $244.55.

AbbVie Trading Down 0.2%

Shares of ABBV opened at $223.45 on Friday. The stock has a market capitalization of $394.92 billion, a PE ratio of 169.28, a P/E/G ratio of 1.21 and a beta of 0.36. The company’s fifty day moving average is $227.25 and its 200 day moving average is $209.59. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.60 and a current ratio of 0.72. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. During the same quarter last year, the business earned $3.00 earnings per share. AbbVie’s quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Sell-side analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a $1.73 dividend. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.1%. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is 496.97%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.